Journal
DIABETES OBESITY & METABOLISM
Volume 17, Issue 8, Pages 800-804Publisher
WILEY-BLACKWELL
DOI: 10.1111/dom.12481
Keywords
24-h glucose variability; continuous glucose monitoring; luseogliflozin; SGLT2 inhibitor; type 2 diabetes
Categories
Funding
- Taisho Pharmaceutical Co., Ltd, Tokyo, Japan
- Taisho Pharmaceutical Co., Ltd.
Ask authors/readers for more resources
The aim of the present study was to determine the effects of luseogliflozin on 24-h glucose levels, assessed by continuous glucose monitoring, and on pharmacodynamic variables measured throughout the day. In this double-blind, placebo-controlled, crossover study, 37 patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized into two groups. Patients in each group first received luseogliflozin then placebo for 7 days each, or vice versa. After 7 days of treatment, the mean 24-h glucose level was significantly lower with luseogliflozin than with placebo [mean (95% confidence interval) 145.9 (134.4-157.5) mg/dl vs 168.5 (156.9-180.0) mg/dl; p < 0.001]. The proportion of time spent with glucose levels >= 70 to <= 180 mg/dl was significantly greater with luseogliflozin than with placebo [median (interquartile range) 83.2 (67.7-96.5)% vs 71.9 (46.9-83.3)%; p < 0.001] without inducing hypoglycaemia. The decrease in glucose levels was accompanied by reductions in serum insulin levels throughout the day.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available